AURA Julie B Feder sells $302K worth of shares
Oct 22, 2024, 10:33 AM
-14.80%
What does AURA do
Aura Biosciences, a clinical-stage oncology company based in Boston, develops virus-like drug conjugates (VDCs) to selectively target cancer cells and activate immune responses. Its lead candidate, bel-sar, is in late-stage clinical development for choroidal melanoma and bladder cancer.
Julie B Feder sold 25,131 shares of AURA on 18 October at $12.03 per share, worth a total of $302K. They now own 134,276 AURA shares, or a 16% holding decrease.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.